TLR2_HUMAN » Toll-like receptor 2

TLR2_HUMAN » Toll-like receptor 2
Magnify TLR2_HUMAN » Toll-like receptor 2Enlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
TLR2_HUMAN » Toll-like receptor 2 » Toll/interleukin-1 receptor-like protein 4;
Hydrophobic Thickness 32.8 ± 1.8 Å
Tilt Angle 0 ± 2°
ΔGtransfer -33.7 kcal/mol
ΔGfold -15.4 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC, Reactome
Topology Out
TM Segments 588-612 (582-613)
Pathways

Amoebiasis (KEGG)

Chagas disease (KEGG)

Hepatitis B (KEGG)

Herpes simplex infection (KEGG)

Immune System (Reactome)

Legionellosis (KEGG)

Leishmaniasis (KEGG)

Malaria (KEGG)

Measles (KEGG)

Phagosome (KEGG)

PI3K-Akt signaling pathway (KEGG)

Proteoglycans in cancer (KEGG)

Rheumatoid arthritis (KEGG)

Toll-like receptor signaling pathway (KEGG)

Toxoplasmosis (KEGG)

Tuberculosis (KEGG)

PDB 2z80 (1-284), 1o77 (A/B...=639-784), 2z7x (A=27-506), 1fyw (A=636-784), 1fyx (A=636-784)
OPM none
Complexes

TLR2:TLR1_HUMAN

TLR6:TLR2:Q4G1L3:Q4G1L2_MOUSE

TLR2:TLR2_HUMAN

Interactions

CD44, Complex: TLR2:CD44, PubMed

CLC4M, Complex: CLC4M:TLR2, PubMed

CLC7A, Complex: TLR2:CLC7A, PubMed

EGFR, Complex: TLR2:EGFR, PubMed

STX17, Complex: STX17:TLR2

TLR10, Complex: TLR2:MYD88:TLR10, PubMed

TLR1, Complex: TLR1:TLR2, PDBID: 2z7x

TLR2, Complex: Homodimer of toll-like receptor 2, PDBID: 1O77

TLR6, Complex: TLR2:TLR6, PDBID: 3a79, PubMed

Domains

AA: 76-135, PDBID: 2Z7X, Subunit A, Seq Identity:100%, Leucine rich repeat

AA: 561-586, PDBID: 1W8A, Subunit A, Seq Identity:34%, Leucine rich repeat C-terminal domain

AA: 640-784, PDBID: 1FYW, Subunit A, Seq Identity:100%, TIR domain

UniProt annotation for TLR2_HUMAN » Toll-like receptor 2
FUNCTION: Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6.

SUBUNIT: Interacts with LY96, TLR1 and TLR6 (via extracellular domain). Binds MYD88 (via TIR domain). Interacts with TICAM1. Ligand binding induces the formation of a heterodimer with TLR1 or TLR6. Interacts with CNPY3 (By similarity). Interacts with ATG16L1.

TISSUE SPECIFICITY: Highly expressed in peripheral blood leukocytes, in particular in monocytes, in bone marrow, lymph node and in spleen. Also detected in lung and in fetal liver. Levels are low in other tissues.

DOMAIN: Ester-bound lipid substrates are bound through a crevice formed between the LRR 11 and LRR 12.

DOMAIN: The ATG16L1-binding motif mediates interaction with ATG16L1.

UniProt features for TLR2_HUMAN » Toll-like receptor 2
SIGNAL 1 18 Potential.
CHAIN 19 784 Toll-like receptor 2.
REPEAT 54 77 LRR 1.
REPEAT 78 101 LRR 2.
REPEAT 102 125 LRR 3.
REPEAT 126 150 LRR 4.
REPEAT 151 175 LRR 5.
REPEAT 176 199 LRR 6.
REPEAT 200 223 LRR 7.
REPEAT 224 250 LRR 8.
REPEAT 251 278 LRR 9.
REPEAT 279 308 LRR 10.
REPEAT 309 337 LRR 11.
REPEAT 338 361 LRR 12.
REPEAT 362 388 LRR 13.
REPEAT 389 414 LRR 14.
REPEAT 415 437 LRR 15.
REPEAT 438 457 LRR 16.
REPEAT 458 478 LRR 17.
REPEAT 479 500 LRR 18.
REPEAT 501 524 LRR 19.
DOMAIN 525 579 LRRCT.
DOMAIN 639 784 TIR.
MOTIF 761 778 ATG16L1-binding motif.
SITE 349 349 Interaction with bacterial lipopeptide.
DISULFID 30 36
DISULFID 353 382
DISULFID 432 454
Amino Acid Sequence for TLR2_HUMAN » Toll-like receptor 2
MPHTLWMVWV LGVIISLSKE ESSNQASLSC DRNGICKGSS GSLNSIPSGL TEAVKSLDLS NNRITYISNS DLQRCVNLQA LVLTSNGINT IEEDSFSSLG SLEHLDLSYN YLSNLSSSWF KPLSSLTFLN LLGNPYKTLG ETSLFSHLTK LQILRVGNMD TFTKIQRKDF AGLTFLEELE IDASDLQSYE PKSLKSIQNV SHLILHMKQH ILLLEIFVDV TSSVECLELR DTDLDTFHFS ELSTGETNSL IKKFTFRNVK ITDESLFQVM KLLNQISGLL ELEFDDCTLN GVGNFRASDN DRVIDPGKVE TLTIRRLHIP RFYLFYDLST LYSLTERVKR ITVENSKVFL VPCLLSQHLK SLEYLDLSEN LMVEEYLKNS ACEDAWPSLQ TLILRQNHLA SLEKTGETLL TLKNLTNIDI SKNSFHSMPE TCQWPEKMKY LNLSSTRIHS VTGCIPKTLE ILDVSNNNLN LFSLNLPQLK ELYISRNKLM TLPDASLLPM LLVLKISRNA ITTFSKEQLD SFHTLKTLEA GGNNFICSCE FLSFTQEQQA LAKVLIDWPA NYLCDSPSHV RGQQVQDVRL SVSECHRTAL VSGMCCALFL LILLTGVLCH RFHGLWYMKM MWAWLQAKRK PRKAPSRNIC YDAFVSYSER DAYWVENLMV QELENFNPPF KLCLHKRDFI PGKWIIDNII DSIEKSHKTV FVLSENFVKS EWCKYELDFS HFRLFDENND AAILILLEPI EKKAIPQRFC KLRKIMNTKT YLEWPMDEAQ REGFWVNLRA AIKS